Maintaining vascular access: the management of hemodialysis arteriovenous grafts.
For the nephrologist and surgeon, maintaining vascular access is a significant challenge in hemodialysis (HD), because the portal is vulnerable to infection, stenosis, and thrombus. Vascular access options for HD include the placement of arteriovenous (AV) fistulas, AV grafts, and double-lumen, cuffed central vein catheters. Catheter use is generally associated with higher rates of infection and could compromise the adequacy of HD. Primary AV fistulas, which are generally recommended and provide excellent HD access, are not always the ideal choice for certain patients, such as the elderly or patients with diabetes mellitus. AV grafts allow for a large surface area available for cannulation, and thrombosed grafts have longer patency rates after revision than do revised fistulas. Although both AV fistulas and AV grafts are vulnerable to thrombosis and/or stenosis, surveillance and techniques such as Doppler ultrasound and intravascular ultrasound can minimize such complications. In addition, pharmacotherapeutic options are being studied to determine whether these complications can be prevented. Studies using a variety of pharmacologic agents have been conducted to determine whether stenosis and graft thrombosis can be prevented and have produced varying results. The use of warfarin can result in significant bleeding, but agents such as fish oil and angiotensin-converting enzyme inhibitors have shown some effect in increasing the patency in AV grafts and fistulas. Additional randomized trials with at least 1 or 2 yrs of follow-up are necessary to assess the long-term use of these pharmacotherapies.
Schild
A Frederick
AF
Florida International University-Herbert Wertheim College of Medicine, Miami, FL, USA. afschild@fiu.edu
D000925:Anticoagulants / Q000627:therapeutic use; D001166:Arteriovenous Shunt, Surgical / Q000009:adverse effects; D019917:Blood Vessel Prosthesis Implantation / Q000009:adverse effects; D002405:Catheterization, Central Venous; D003251:Constriction, Pathologic; D019317:Evidence-Based Medicine; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006083:Graft Occlusion, Vascular / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D006435:Renal Dialysis; D013927:Thrombosis / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D016896:Treatment Outcome; D014654:Vascular Patency
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors